KR20240170956A - 암 치료를 위한 병용 요법 - Google Patents

암 치료를 위한 병용 요법 Download PDF

Info

Publication number
KR20240170956A
KR20240170956A KR1020247036943A KR20247036943A KR20240170956A KR 20240170956 A KR20240170956 A KR 20240170956A KR 1020247036943 A KR1020247036943 A KR 1020247036943A KR 20247036943 A KR20247036943 A KR 20247036943A KR 20240170956 A KR20240170956 A KR 20240170956A
Authority
KR
South Korea
Prior art keywords
azd5305
pharmaceutically acceptable
acceptable salt
prostate cancer
darolutamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247036943A
Other languages
English (en)
Korean (ko)
Inventor
사비나 키아라 코술리치
제시카 에스 브라운
마크 알 알베르텔라
엘리자베타 레오
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20240170956A publication Critical patent/KR20240170956A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247036943A 2022-04-07 2023-04-06 암 치료를 위한 병용 요법 Pending KR20240170956A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362612P 2022-04-07 2022-04-07
US63/362,612 2022-04-07
PCT/EP2023/059126 WO2023194528A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
KR20240170956A true KR20240170956A (ko) 2024-12-05

Family

ID=86185292

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247036943A Pending KR20240170956A (ko) 2022-04-07 2023-04-06 암 치료를 위한 병용 요법

Country Status (11)

Country Link
US (1) US20250235448A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504180A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511401A (cg-RX-API-DMAC7.html)
KR (1) KR20240170956A (cg-RX-API-DMAC7.html)
CN (1) CN118973572A (cg-RX-API-DMAC7.html)
AU (1) AU2023248685A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254948A1 (cg-RX-API-DMAC7.html)
IL (1) IL316016A (cg-RX-API-DMAC7.html)
MX (1) MX2024012368A (cg-RX-API-DMAC7.html)
TW (1) TW202404593A (cg-RX-API-DMAC7.html)
WO (1) WO2023194528A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240325384A1 (en) * 2023-03-31 2024-10-03 Astrazeneca Ab Dosing regimen
WO2026021478A1 (zh) * 2024-07-23 2026-01-29 江苏恒瑞医药股份有限公司 Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Also Published As

Publication number Publication date
JP2025511401A (ja) 2025-04-15
TW202404593A (zh) 2024-02-01
MX2024012368A (es) 2024-11-08
CA3254948A1 (en) 2023-10-12
IL316016A (en) 2024-11-01
AU2023248685A1 (en) 2024-11-14
EP4504180A1 (en) 2025-02-12
US20250235448A1 (en) 2025-07-24
WO2023194528A1 (en) 2023-10-12
CN118973572A (zh) 2024-11-15

Similar Documents

Publication Publication Date Title
AU2013205648B2 (en) Combination treatment
WO2023194528A1 (en) Combination therapy for treating cancer
KR20240170957A (ko) 암 치료를 위한 병용 요법
TW202425976A (zh) 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
CN115038447A (zh) 用于治疗癌症的组合疗法
US20250228847A1 (en) Combination therapy for treating cancer
US9867865B1 (en) Mesalamine for the treatment of cancer
KR102005887B1 (ko) 뇌종양의 예방 또는 치료용 약학 조성물
JP2026515235A (ja) 癌を治療するためのparp1阻害剤と選択的エストロゲン分解薬の併用
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
TW202600137A (zh) 於使用parp抑制劑的治療作為預測性生物標記之tmprss2-erg和rbi及使用parp抑制劑之治療方法
KR20260020107A (ko) 다발성 경화증을 치료하기 위한 btk 억제제
WO2025242217A1 (zh) 一种含噻吩并嘧啶化合物的药物组合物、其制备方法及用途
CN118043051A (zh) 用于治疗或预防抗宿主病的吡咯并六元杂芳物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20241105

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application